EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance
Liping Chu(ShanghaiTech University), Wei Qi(Jilin University)
Cited by 18
Related Papers
Structure and Substrate Recruitment of the Human Spindle Checkpoint Kinase Bub1
|Molecular Cell|2008|108
Targeting the Wnt-Regulatory Protein CTNNBIP1 by microRNA-214 Enhances the Stemness and Self-Renewal of Cancer Stem-Like Cells in Lung Adenocarcinomas
|Stem Cells|2015|41
Induction of senescence-associated secretory phenotype underlies the therapeutic efficacy of PRC2 inhibition in cancer
|Cell Death and Disease|2022|38
PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors
|Journal of Biological Chemistry|2024|15